Agilent Research Catalyst Award Presented to Columbia University for Professor Pawel Muranski
Agilent Technologies (NYSE: A) has awarded Columbia University an Agilent Research Catalyst (ARC) Award for Dr. Pawel Muranski's groundbreaking work in cellular immunotherapy. Dr. Muranski, Director of Cellular Immunotherapy Laboratory at Columbia University Irving Medical Center, is developing a novel cGMP platform for generating clinical-grade multi-specific CD4+ cytotoxic T cells to treat various cancers.
The award includes research funding and advanced Agilent instruments including a Seahorse XF Pro Analyzer, xCELLigence RTCA MP instrument, NovoCyte Penteon Flow Cytometer, BioTek Cytation 1 Cell Imaging Reader, and BioTek 800 TS Absorbance Reader. These tools will help accelerate the development of innovative manufacturing methods and establish standardized quality control assays for anti-cancer T cell production.
Agilent Technologies (NYSE: A) ha conferito all'Università di Columbia un Agilent Research Catalyst (ARC) Award per il lavoro innovativo del Dr. Pawel Muranski nella immunoterapia cellulare. Il Dr. Muranski, Direttore del Laboratorio di Immunoterapia Cellulare presso il Columbia University Irving Medical Center, sta sviluppando una nuova piattaforma cGMP per la generazione di cellule T citotossiche CD4+ multi-specifiche di grado clinico per trattare vari tipi di cancro.
Il premio include finanziamenti per la ricerca e strumenti avanzati Agilent, tra cui un Seahorse XF Pro Analyzer, uno strumento xCELLigence RTCA MP, un NovoCyte Penteon Flow Cytometer, un BioTek Cytation 1 Cell Imaging Reader e un BioTek 800 TS Absorbance Reader. Questi strumenti aiuteranno ad accelerare lo sviluppo di metodi di produzione innovativi e a stabilire saggi di controllo qualità standardizzati per la produzione di cellule T anti-cancro.
Agilent Technologies (NYSE: A) ha otorgado a la Universidad de Columbia un Agilent Research Catalyst (ARC) Award por el trabajo innovador del Dr. Pawel Muranski en la inmunoterapia celular. El Dr. Muranski, Director del Laboratorio de Inmunoterapia Celular en el Columbia University Irving Medical Center, está desarrollando una nueva plataforma cGMP para generar células T citotóxicas CD4+ multispecíficas de grado clínico para tratar varios tipos de cáncer.
El premio incluye financiación para la investigación y avanzados instrumentos de Agilent, incluyendo un Seahorse XF Pro Analyzer, un instrumento xCELLigence RTCA MP, un NovoCyte Penteon Flow Cytometer, un BioTek Cytation 1 Cell Imaging Reader y un BioTek 800 TS Absorbance Reader. Estas herramientas ayudarán a acelerar el desarrollo de métodos de fabricación innovadores y a establecer ensayos de control de calidad estandarizados para la producción de células T anti-cáncer.
Agilent Technologies (NYSE: A)는 컬럼비아 대학교에 Dr. Pawel Muranski의 획기적인 세포 면역 치료 연구에 대해 Agilent Research Catalyst (ARC) Award를 수여했습니다. Muranski 박사는 컬럼비아 대학교 어빙 메디컬 센터의 세포 면역 치료 연구소 소장으로, 다양한 암을 치료하기 위해 임상 등급의 다중 특이적 CD4+ 세포 독성 T 세포를 생성하는 새로운 cGMP 플랫폼을 개발하고 있습니다.
이 상은 연구 자금과 함께 Seahorse XF Pro 분석기, xCELLigence RTCA MP 기기, NovoCyte Penteon 유세포 분석기, BioTek Cytation 1 세포 이미징 리더 및 BioTek 800 TS 흡광도 리더와 같은 고급 Agilent 기기를 포함합니다. 이러한 도구들은 혁신적인 제조 방법 개발을 가속화하고 항암 T 세포 생산을 위한 표준화된 품질 관리 분석을 구축하는 데 도움이 될 것입니다.
Agilent Technologies (NYSE: A) a décerné à l'Université de Columbia un Agilent Research Catalyst (ARC) Award pour le travail révolutionnaire du Dr. Pawel Muranski dans le domaine de l'immunothérapie cellulaire. Le Dr. Muranski, directeur du laboratoire d'immunothérapie cellulaire au Columbia University Irving Medical Center, développe une nouvelle plateforme cGMP pour générer des cellules T cytotoxiques CD4+ multi-spécifiques de qualité clinique pour traiter divers cancers.
Le prix comprend un financement de recherche et des instruments Agilent avancés, notamment un Seahorse XF Pro Analyzer, un instrument xCELLigence RTCA MP, un NovoCyte Penteon Flow Cytometer, un BioTek Cytation 1 Cell Imaging Reader et un BioTek 800 TS Absorbance Reader. Ces outils aideront à accélérer le développement de méthodes de fabrication innovantes et à établir des tests de contrôle qualité standardisés pour la production de cellules T anti-cancer.
Agilent Technologies (NYSE: A) hat der Columbia University einen Agilent Research Catalyst (ARC) Award für die bahnbrechende Arbeit von Dr. Pawel Muranski in der zellulären Immuntherapie verliehen. Dr. Muranski, Direktor des Laboratoriums für zelluläre Immuntherapie am Columbia University Irving Medical Center, entwickelt eine neuartige cGMP-Plattform zur Erzeugung klinisch einsetzbarer multi-spezifischer CD4+ zytotoxischer T-Zellen zur Behandlung verschiedener Krebserkrankungen.
Der Preis umfasst Forschungsfinanzierung und fortschrittliche Agilent-Geräte, darunter einen Seahorse XF Pro Analyzer, ein xCELLigence RTCA MP-Gerät, ein NovoCyte Penteon Flusszytometer, einen BioTek Cytation 1 Zellbildleser und einen BioTek 800 TS Absorptionsleser. Diese Werkzeuge werden helfen, die Entwicklung innovativer Herstellungsverfahren zu beschleunigen und standardisierte Qualitätskontrolltests für die Produktion von anti-krebs T-Zellen zu etablieren.
- Strategic investment in cutting-edge cancer therapy research
- Expansion of Agilent's presence in the growing cellular immunotherapy market
- Partnership with prestigious research institution (Columbia University)
- None.
Scientist recognized for pioneering advances in bioprocess development and biomanufacturing
Dr. Muranski is the Director of Cellular Immunotherapy Laboratory at Columbia University Irving Medical Center. He is also an Assistant Professor of Medicine at Columbia University Medical Center, a principal investigator at the Columbia Center for Translational Immunology (CCTI), and a member of the Herbert Irving Comprehensive Cancer Center. The award acknowledges Dr. Muranski’s ongoing efforts to develop live-cell analytical assays and workflows for bioprocess development and biomanufacturing of cell therapeutics under the current Good Manufacturing Practice (cGMP) guidelines and regulations.
Dr. Muranski’s research at
“Cellular immunotherapy has transformed modern oncology, offering the potential for fully curative cancer treatments. However, given the personalized and labor-intensive nature of cellular therapies, significant challenges remain to fully achieve this goal,” stated Dr. Muranski. “We are excited to leverage advanced technologies and solutions from Agilent to enhance, streamline, and automate these therapies. Initially, we will use these tools to accelerate the development of innovative manufacturing methods. Subsequently, we will apply the same solutions to establish robust, standardized quality control assays essential for the routine production of anti-cancer T cells for patients in our clinical trials. We are very grateful to Agilent for supporting our work at Columbia.”
“Agilent is committed to expanding the frontiers of bioprocess development and biomanufacturing for advanced therapies. We are thrilled to present this ARC Award to
"Dr. Muranski's innovative approach to developing a cGMP platform for generating clinical-grade multi-specific CD4+ cytotoxic T cells is a significant leap forward in the field of cell therapeutics,” added Xavier Amouretti, vice president and general manager of the BioTek product line at Agilent. “By providing advanced analytical tools and resources, we aim to empower researchers like Dr. Muranski to push the boundaries of science and accelerate the development of transformative therapies for patients worldwide.”
The ARC Award program is committed to fostering scientific advancement and supporting noteworthy university research in life sciences, diagnostics, and chemical analysis by providing financial aid, products, and expertise. For more information, visit the Agilent Research Catalyst (ARC) program web page.
About Agilent Technologies
Agilent Technologies Inc. (NYSE: A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of
View source version on businesswire.com: https://www.businesswire.com/news/home/20250319344447/en/
Media Contact
Naomi Goumillout
Agilent Technologies
+1.978.314.1862
naomi.goumillout@agilent.com
Source: Agilent Technologies Inc.
FAQ
What is the significance of Agilent's ARC Award to Columbia University for cancer research?
How will Dr. Muranski use Agilent's equipment for cancer treatment development?
What types of cancers will be targeted by Dr. Muranski's research at Columbia University?
What specific equipment did Agilent (NYSE: A) provide in the ARC Award package?
